Mihailidis Vasilios, Anevlavis Stavros, Karpathiou Georgia, Kouliatsis George, Tzouvelekis Argyrios, Zarogoulidis Paul, Ntolios Paschalis, Steiropoulos Paschalis, Bouros Demosthenes, Froudarakis Marios E
Departments of Respiratory Medicine, Medical School Democritus University of Thrace, Alexandroupolis, Greece.
J Thorac Dis. 2018 Sep;10(9):5435-5442. doi: 10.21037/jtd.2018.08.139.
Reports point out lung toxicity of chemotherapeutic agents and radiation therapy in cancer patients. The aim of our study was to assess lung function after sequential chemoradiation therapy in patients with lung cancer.
Fifteen lung cancer patients participated the study and underwent lung function assessment before and after sequential treatment of chemotherapy with the 3 most applied platinum-based combinations: of vinorelbine (VN) 6 patients, gemcitabine (GEM) 4 patients and etoposide (EP) 5 patients and radiation therapy. Lung function tests were forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), total lung capacity (TLC), diffusing capacity for carbon monoxide (DL) and carbon monoxide transfer coefficient (Kco).
Mean patients' age was 58±9.4 years (42-75 years). Male patients were 14 (93.3%), all smokers. Overall, after chemoradiation treatment significant changes were noted in FEV1 (P=0.012), FVC (P=0.046), TLC (P=0.04) from baseline. The drop from baseline was more significant after chemoradiation therapy in DLCO (P=0.002) and KCO (P=0.008).
According to our results, sequential chemoradiation causes significant changes in lung function parameters in patients with lung cancer.
报告指出化疗药物和放射治疗对癌症患者的肺部毒性。我们研究的目的是评估肺癌患者序贯放化疗后的肺功能。
15例肺癌患者参与了本研究，在接受3种最常用的铂类联合化疗方案（长春瑞滨（VN）6例、吉西他滨（GEM）4例、依托泊苷（EP）5例）及放射治疗的序贯治疗前后进行了肺功能评估。肺功能测试包括一秒用力呼气容积（FEV1）、用力肺活量（FVC）、肺总量（TLC）、一氧化碳弥散量（DL）和一氧化碳转移系数（Kco）。
患者平均年龄为58±9.4岁（42 - 75岁）。男性患者14例（93.3%），均为吸烟者。总体而言，放化疗后FEV1（P = 0.012）、FVC（P = 0.046）、TLC（P = 0.04）较基线有显著变化。放化疗后DLCO（P = 0.002）和KCO（P = 0.008）较基线下降更为显著。
根据我们的结果,序贯放化疗会导致肺癌患者肺功能参数发生显著变化。
